Oscar Gershanik, MD, Favaloro University, Buenos Aires, Argentina, discusses the current focus in Parkinson’s disease research, which is on defining the disease and identifying biomarkers for early detection. The ultimate goal is to develop targeted drugs that work on individual patients based on their specific mechanisms rather than a one-size-fits-all approach. Although we have yet to reach that stage, Prof. Gershanik remains hopeful that within the next two to five years, significant progress will be made. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
